Trial Profile
A Phase I/II Study of Ribociclib, a CDK4/6 Inhibitor, Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ribociclib (Primary) ; Ribociclib (Primary)
- Indications Diffuse intrinsic pontine glioma; Glioma
- Focus Adverse reactions; Therapeutic Use
- 15 Oct 2020 Status changed from active, no longer recruiting to discontinued.
- 09 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Apr 2016 Status changed from not yet recruiting to recruiting.